Search - tctmd.com

Displaying 41 - 60 of 423

Sort: Relevancy | Date

News Conference News ACC 2024

Need a Statin for Primary Prevention? There’s an App for That

Michael O'Riordan

April 10, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

News Conference News ACC 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Yael L. Maxwell

April 07, 2024

News Conference News ACC 2024

Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI

Michael O'Riordan

April 07, 2024

News Conference News ACC 2024

Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI

Yael L. Maxwell

April 06, 2024

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Todd Neale

March 27, 2024

News Conference News CRT 2024

Full AGENT IDE Results Affirm Benefits of DCB for In-Stent Restenosis

L.A. McKeown

March 09, 2024

News Conference News AHA 2023

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

Todd Neale

November 17, 2023

News Conference News AHA 2023

Automatic Scripts, Pharmacist Phone Calls Boost Statin Prescribing

Shelley Wood

November 14, 2023

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Shelley Wood

November 13, 2023

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

News Conference News AHA 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

Shelley Wood

November 11, 2023

News Conference News TCT 2023

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

Michael O'Riordan

November 01, 2023

News Conference News TCT 2023

Does Thrombolysis Have a Role in a Primary-PCI World? Experts Hash It Out

Michael O'Riordan

October 25, 2023

News Conference News TCT 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Yael L. Maxwell

October 25, 2023

News Conference News EACTS 2023

Surgeons Support Proposed Changes to Left Main CAD Guidelines

Michael O'Riordan

October 13, 2023

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

News Conference News ESC 2023

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

L.A. McKeown

September 01, 2023

News Conference News ESC 2023

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

Michael O'Riordan

September 01, 2023

News Conference News ESC 2023

More Details on Acoramidis’ Benefit in ATTR Cardiomyopathy: ATTRibute-CM

Michael O'Riordan

August 31, 2023

Advertisement

Need a Statin for Primary Prevention? There’s an App for That

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI

Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Full AGENT IDE Results Affirm Benefits of DCB for In-Stent Restenosis

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

Automatic Scripts, Pharmacist Phone Calls Boost Statin Prescribing

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

Does Thrombolysis Have a Role in a Primary-PCI World? Experts Hash It Out

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Surgeons Support Proposed Changes to Left Main CAD Guidelines

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

More Details on Acoramidis’ Benefit in ATTR Cardiomyopathy: ATTRibute-CM

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content